GlassScriptPhysician profile
Jennifer Snyder
NPI 1770573040
$14,255.11
in general payments reported to CMS, 2019-2025
56 companies · $2,662 in 2025
The $2,662 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,890 · 2022: $3,001 · 2023: $3,057 · 2024: $2,645 · 2025: $2,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,129 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,128.86 |
| Education | $235.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,929.53 | 2021-2025 | |
| Novo Nordisk INC | $1,210.83 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $907.75 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $645.93 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $569.26 | 2021-2025 | Pifeltro, Dificid, Capvaxive |
| Amgen INC. | $539.39 | 2021-2025 | Otezla, Repatha, Prolia |
| Axsome Therapeutics, INC. | $529.19 | 2023-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $514.52 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Sumitomo Pharma America, INC. | $469.21 | 2023-2024 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $458.23 | 2021-2025 | Nuzyra, Xhance |
| Corium, LLC | $432.68 | 2022-2025 | Azstarys |
| Mylan Specialty L.P. | $405.11 | 2021-2024 | Yupelri |
| Napo Pharmaceuticals INC | $382.37 | 2021-2024 | Mytesi |
| Takeda Pharmaceuticals U.S.A., INC. | $325.31 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $323.51 | 2021-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290.55 | 2021-2025 | Airsupra, Breztri |
| Lundbeck LLC | $281.84 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $251.51 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Antares Pharma, INC. | $245.83 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Viiv Healthcare Company | $213.59 | 2021-2025 | Dovato, Apretude |
| Phathom Pharmaceuticals, INC. | $195.74 | 2024-2025 | Voquezna |
| Abbott Laboratories | $189.82 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $186.90 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $186.82 | 2023-2025 | Veozah, Myrbetriq |
| Ardelyx, INC. | $165.09 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $157.90 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $156.63 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $155.93 | 2021-2023 | Seglentis, Livalo |
| Biohaven Pharmaceutical Holding Company LTD. | $143.92 | 2022 | |
| Amarin Pharma, INC. | $142.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.29 | 2021-2025 | |
| Gilead Sciences, INC. | $129.56 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $105.40 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.08 | 2024-2025 | Caplyta |
| Esperion Therapeutics, INC. | $101.32 | 2021 | |
| Exact Sciences Corporation | $97.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $90.62 | 2023-2024 | Quviviq |
| Eisai INC. | $78.68 | 2021-2022 | |
| Dexcom, INC. | $77.59 | 2021-2024 | Dexcom G6 Transmitter |
| Verity Pharmaceuticals INC. | $73.00 | 2025 | Tlando |
| Theratechnologies INC. | $70.01 | 2021 | |
| Insulet Corporation | $67.58 | 2021-2023 | Omnipod |
| Endo Pharmaceuticals INC. | $63.30 | 2021-2022 | |
| Emd Serono, INC. | $57.31 | 2021-2024 | |
| Halozyme INC | $51.51 | 2023 | |
| Supernus Pharmaceuticals, INC. | $48.94 | 2021-2022 | Xyosted |
| Genentech USA, INC. | $42.30 | 2021 | |
| Viatris Specialty LLC | $41.45 | 2025 | Yupelri |
| Radius Health, INC. | $37.58 | 2025 | |
| Biogen, INC. | $36.16 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $31.64 | 2021 | |
| Janssen Products, LP | $31.49 | 2021 | |
| Inspire Medical Systems, INC. | $23.06 | 2023 | Inspire |
| Janssen Biotech, INC. | $19.79 | 2021-2023 | Symtuza |
| Neurocrine Biosciences, INC. | $17.02 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.